GEN Exclusives

More »

GEN News Highlights

More »
Mar 20, 2007

Cannasat Taps IntelGenx to Facilitate Development of Cannabinoid-Based Products for Mood Disorders

  • Cannasat Therapeutics and IntelGenx will together develop a cannabinoid-based product through a combination of Cannasat's and IntelGenx's drug delivery technologies. CAT 320 targets the endocannabinoid system to treat mood disorders, such as anxiety and depression.

    Cannasat will leverage IntelGenx' experience in developing oral, sublingual, and transdermal formulations. IntelGenx' will help address the challenges of achieving rapid onset, improving therapeutic efficacy, and minimizing the total dose required to treat disease conditions.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Genetics and Intelligence

Do you believe research on the genetics of intelligence can improve education?

More »